Asthma Empowerment Collaborations to Reduce Childhood Asthma Disparities (U01)

The summary for the Asthma Empowerment Collaborations to Reduce Childhood Asthma Disparities (U01) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Asthma Empowerment Collaborations to Reduce Childhood Asthma Disparities (U01): The purpose of this FOA is to support clinical trials to evaluate Asthma Care Implementation Programs (ACIP) that provide comprehensive care for children at high risk of poor asthma outcomes. The community-based ACIPs are expected to address the needs of the U.S. community in which the study will be conducted and integrate interventions with demonstrated efficacy from four different sectors (medical care, family, home, and community). Applications must include a trial designed to assess if the ACIP improves asthma outcomes relative to an appropriate comparator(s) and a subsequent period of observation to evaluate sustainability. While there are several other necessary elements of the trials, it is critical that the outcomes/endpoints include measures of the process used to implement the evidence based interventions. The ACIP will involve investigators who have established collaborations with representatives from the four sectors who have committed resources to the ACIP. Given the potential impact of the interventions on the local community, the sustainability of the program will be formally assessed during the project period. Finally, investigators must plan for dissemination of the program beyond their own community. This initiative is designed as a cooperative agreement to enable collaboration among investigators on the implementation metrics to be used, the quality improvement efforts to be conducted throughout the funding period, and how to establish best practices.

Federal Grant Title:	Asthma Empowerment Collaborations to Reduce Childhood Asthma Disparities (U01)
Federal Agency Name:	National Institutes of Health
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-HL-17-001
Type of Funding:	Cooperative Agreement
CFDA Numbers:	93.838
CFDA Descriptions:	Lung Diseases Research
Current Application Deadline:	Nov 16, 2016
Original Application Deadline:	Nov 16, 2016
Posted Date:	Dec 9, 2014
Creation Date:	Dec 9, 2014
Archive Date:	Dec 17, 2016
Total Program Funding:
Maximum Federal Grant Award:	none
Minimum Federal Grant Award:	none
Expected Number of Awards:	4
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: Native American tribal governments (Federally recognized)
Independent school districts
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Private institutions of higher education
Small businesses
County governments
Public housing authorities/Indian housing authorities
Native American tribal organizations (other than Federally recognized tribal governments)
For profit organizations other than small businesses
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
State governments
Special district governments
City or township governments
Public and State controlled institutions of higher education
Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility: Other Eligible Applicants include the following:
Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-17-001.html
Grant Announcement Contact: NIH OER Webmaster [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

National Institutes of Health 301-496-3405
Similar Government Grants: • Limited Competition: Physician Scientist Transition to Independence in Blood Science Resea...; • Single Source: Molecular Atlas of Lung Development Program (LungMAP) Phase 3 - Data Coordi...; • Single Source: Molecular Atlas of Lung Development Program (LungMAP) Phase 3 - Human Tissu...; • Molecular Atlas of Lung Development Program (LungMAP) Phase 3 - Research Centers (U01 Clin...; • Pathogenesis of Sars Lung Disease: in Vitro Studies and Animal Models; • Lung Response to Inhaled Highly Toxic Chemicals; • Protein Interactions Governing Membrane Transport in Pulmonary Health and Disease (R01)
More Grants from the National Institutes of Health: • Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Tri...; • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...; • HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggabl...; • Optimizing Behavioral Sleep Interventions for Adolescents and Young Adults (R34 Clinical T...; • Global Infectious Disease Research Training Program (D43 Clinical Trial Optional)